PharmaSGP
| PharmaSGP Holding SE | |
|---|---|
| legal form | European society |
| ISIN | DE000A2P4LJ5 |
| founding | 2009 |
| Seat | Graefelfing |
| management | Natalie Weigand, CEO
Michael Rudolf, CFO Dr. Clemens Fischer, chairman of the supervisory board |
| Number of employees | 53 |
| sales | 62.6 million euros |
| Branch | Pharmaceutical industry |
| Website | www.sgp-pharma.com |
| As of July 17, 2020 | |
PharmaSGP Holding SE (also PharmaSGP), based in Graefelfing near Munich, is a German, listed pharmaceutical company that specializes in the development and sale of non-prescription drugs (OTC "over the counter") as well as other health products such as dietary supplements and cosmetics .
history
PharmaSGP was founded in 2008 under the name “Dr. Fischer Health Products ”by Clemens Fischer as part of the international FUTRUE Group. The company laid the foundation for its current portfolio in Germany in 2012 with the launch of the non-prescription, homeopathic drug Deseo for the treatment of sexual weakness in men and women. Since then, the company has expanded its product portfolio to include other pharmaceuticals such as Rubaxx for rheumatic joint pain and Restaxil for nerve pain. In addition to pain therapy and sexual weakness, symptoms associated with dizziness and skin aging are further fields of activity of PharmaSGP. PharmaSGP's products are sold exclusively in pharmacies.
In 2015 the company received the inspirato Pharma Marketing Award in the “OTC Company of the Year” category.
In Germany, PharmaSGP was one of the fastest growing OTC pharmaceutical companies in 2018/2019. In addition to the product portfolio, the pharmaceutical company has also expanded its regional presence in Europe in recent years. In addition to its home market of Germany, PharmaSGP has also been active in Austria, Italy, Belgium, Spain and France since 2016. At the end of May 2020, the company announced its plans to go public.
The shares of PharmaSGP Holding SE have been traded on the regulated market ( Prime Standard ) of the Frankfurt Stock Exchange since June 19, 2020 . With an issue price of EUR 31.50 per share, the market capitalization at the time of the IPO was EUR 378 million. The company itself did not receive any money when it went public, since no new shares were issued from a capital increase , but shares from the holdings of the existing shareholders were placed.
Web links
Individual evidence
- ↑ PharmaSGP Holding SE | OnVista stock exchange forum. Retrieved August 10, 2020 .
- ↑ IPO: Pharmaceutical manufacturer PharmaSGP plans to go public in Frankfurt. Retrieved July 17, 2020 .
- ↑ FUTUE | #Rethink Health. Retrieved on August 10, 2020 (German, English).
- ↑ PharmaSGP. Retrieved on July 17, 2020 (German).
- ↑ PHARMASGP HOLDING share - A2P4LJ - DE000A2P4LJ5 - THE SHAREHOLDER. Retrieved July 17, 2020 .
- ↑ Andrea Zeinar-Steck: The inspirato conference 2015 in review . In: inspirato CONFERENCES, A division of: SEMPORA Consulting GmbH (Ed.): PHARMA MARKETING . tape 2015 , no. 01 . Apo-Verlag AG, Triesen 2015, p. 16 ( inspirato.de [PDF]).
- ↑ PharmaSGP: Growth miracle in the OTC market. Retrieved July 17, 2020 .
- ↑ Pharmacy Adhoc: PharmaSGP wants to buy. Retrieved on July 17, 2020 (German).
- ↑ PharmaSGP Holding SE plans IPO - dgap.de. Retrieved July 17, 2020 .
- ↑ PharmaSGP Holding SE is valued at 378 million euros when it goes public - dgap.de. Retrieved July 17, 2020 .